Found 9 matching trials
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery PHASE1 RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of th...
Show More Location
Addenbrooke's Hospital
Learn More & Join Trial
Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer PHASE4 The purpose of this research project is to study the effect of a research (...
Show More Location
Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center
Learn More & Join Trial
A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor PHASE1 The purpose of this study is to determine the transcriptional signature of ...
Show More Location
Multiple Locations
Learn More & Join Trial
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) PHASE1 This is a two part study of the drug MK-8669 (ridaforolimus) given with MK-...
Show More Location
Multiple Locations
Learn More & Join Trial
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer PHASE1 New and better therapies for locally advanced and metastatic breast cancer ...
Show More Location
Dana Farber Cancer Institute
Learn More & Join Trial
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) PHASE1 An investigational study to determine the safety/tolerability, and efficacy...
Show More Location
Multiple Locations
Learn More & Join Trial
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) PHASE1 This is an open-label, two-part study to evaluate the safety and tolerabili...
Show More Location
Multiple Locations
Learn More & Join Trial
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) PHASE1 A Notch signalling pathway inhibitor study in pediatric and adult patients ...
Show More Location
Multiple Locations
Learn More & Join Trial
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer PHASE1 RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of th...
Show More Location
UCSF Helen Diller Family Comprehensive Cancer Center
Learn More & Join Trial